Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26


BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.

Drost R, Dhillon KK, van der Gulden H, van der Heijden I, Brandsma I, Cruz C, Chondronasiou D, Castroviejo-Bermejo M, Boon U, Schut E, van der Burg E, Wientjens E, Pieterse M, Klijn C, Klarenbeek S, Loayza-Puch F, Elkon R, van Deemter L, Rottenberg S, van de Ven M, Dekkers DH, Demmers JA, van Gent DC, Agami R, Balmaña J, Serra V, Taniguchi T, Bouwman P, Jonkers J.

J Clin Invest. 2016 Aug 1;126(8):2903-18. doi: 10.1172/JCI70196. Epub 2016 Jul 25.


Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, Drost R, Wientjens E, Ji J, Aly A, Doroshow JH, Cranston A, Martin NM, Lau A, O'Connor MJ, Ganesan S, Borst P, Jonkers J, Rottenberg S.

Cancer Discov. 2013 Jan;3(1):68-81. doi: 10.1158/2159-8290.CD-12-0049. Epub 2012 Oct 25.


Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5.

Reid G, Wielinga P, Zelcer N, De Haas M, Van Deemter L, Wijnholds J, Balzarini J, Borst P.

Mol Pharmacol. 2003 May;63(5):1094-103.


Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells.

Wielinga PR, Reid G, Challa EE, van der Heijden I, van Deemter L, de Haas M, Mol C, Kuil AJ, Groeneveld E, Schuetz JD, Brouwer C, De Abreu RA, Wijnholds J, Beijnen JH, Borst P.

Mol Pharmacol. 2002 Dec;62(6):1321-31.


Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance.

Allen JD, Brinkhuis RF, van Deemter L, Wijnholds J, Schinkel AH.

Cancer Res. 2000 Oct 15;60(20):5761-6.


Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport.

Evers R, Kool M, Smith AJ, van Deemter L, de Haas M, Borst P.

Br J Cancer. 2000 Aug;83(3):366-74.


Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs.

Wijnholds J, Mol CA, van Deemter L, de Haas M, Scheffer GL, Baas F, Beijnen JH, Scheper RJ, Hatse S, De Clercq E, Balzarini J, Borst P.

Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7476-81.


Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug.

Jonker JW, Wagenaar E, van Deemter L, Gottschlich R, Bender HM, Dasenbrock J, Schinkel AH.

Br J Pharmacol. 1999 May;127(1):43-50.


Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain.

Bakos E, Evers R, Szakács G, Tusnády GE, Welker E, Szabó K, de Haas M, van Deemter L, Borst P, Váradi A, Sarkadi B.

J Biol Chem. 1998 Nov 27;273(48):32167-75.


Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA.

Evers R, Kool M, van Deemter L, Janssen H, Calafat J, Oomen LC, Paulusma CC, Oude Elferink RP, Baas F, Schinkel AH, Borst P.

J Clin Invest. 1998 Apr 1;101(7):1310-9.


Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1.

Evers R, Cnubben NH, Wijnholds J, van Deemter L, van Bladeren PJ, Borst P.

FEBS Lett. 1997 Dec 8;419(1):112-6.


Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins.

Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, Zijlmans JM, Fibbe WE, Borst P.

Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):4028-33.


Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells.

Evers R, Zaman GJ, van Deemter L, Jansen H, Calafat J, Oomen LC, Oude Elferink RP, Borst P, Schinkel AH.

J Clin Invest. 1996 Mar 1;97(5):1211-8.


Multidrug resistance and the role of P-glycoprotein knockout mice.

Schinkel AH, Mol CA, Wagenaar E, van Deemter L, Smit JJ, Borst P.

Eur J Cancer. 1995 Jul-Aug;31A(7-8):1295-8. Review.


Characterization of the promoter region of the human MDR3 P-glycoprotein gene.

Smit JJ, Mol CA, van Deemter L, Wagenaar E, Schinkel AH, Borst P.

Biochim Biophys Acta. 1995 Mar 14;1261(1):44-56.


Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs.

Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP, et al.

Cell. 1994 May 20;77(4):491-502.


Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease.

Smit JJ, Schinkel AH, Oude Elferink RP, Groen AK, Wagenaar E, van Deemter L, Mol CA, Ottenhoff R, van der Lugt NM, van Roon MA, et al.

Cell. 1993 Nov 5;75(3):451-62.


Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals.

Borst P, Schinkel AH, Smit JJ, Wagenaar E, Van Deemter L, Smith AJ, Eijdems EW, Baas F, Zaman GJ.

Pharmacol Ther. 1993 Nov;60(2):289-99. Review.


Mutation of the human neu protein facilitates down-modulation by monoclonal antibodies.

van Leeuwen F, van de Vijver MJ, Lomans J, van Deemter L, Jenster G, Akiyama T, Yamamoto T, Nusse R.

Oncogene. 1990 Apr;5(4):497-503.


Transient expression of the proto-oncogene int-1 during differentiation of P19 embryonal carcinoma cells.

Schuuring E, van Deemter L, Roelink H, Nusse R.

Mol Cell Biol. 1989 Mar;9(3):1357-61.


Identification of the Mtv-2 gene responsible for the early appearance of mammary tumors in the GR mouse by nucleic acid hybridization.

Michalides R, van Deemter L, Nuss RR, van Nie R.

Proc Natl Acad Sci U S A. 1978 May;75(5):2368-72.

Supplemental Content

Loading ...
Support Center